Gavi, the Vaccine Alliance
Gavi, the Vaccine Alliance is a Geneva-based public-private partnership founded in 2000 that finances and coordinates immunization programmes across 78 lower-income countries, leveraging innovative finance, UNICEF procurement, and donor capital to vaccinate over half the world's children against 20 infectious diseases.
- Company typePrivate
- Founded2000
- HeadquartersGeneva, Switzerland
- Headcount51–100
- GTM typeB2B
- OfferingServices
What Gavi, the Vaccine Alliance does
Gavi, the Vaccine Alliance is a Swiss foundation with international institution status, founded in 2000 as a public-private partnership to expand equitable access to immunization in lower-income countries. It operates as a market-shaping financing platform that aggregates vaccine demand across 78 eligible lower-income countries, negotiates volume-based pricing with manufacturers, and channels capital and technical assistance through implementing governments and multilateral partners including UNICEF (procurement), WHO (technical guidance), and the World Bank (financing). Its core technology is the market-shaping mechanism itself: innovative finance instruments including the International Finance Facility for Immunisation (IFFIm), the Pneumococcal Advance Market Commitment (AMC), the Gavi Matching Fund, and the Day Zero Financing Facility, which collectively mobilize sovereign donor capital, philanthropic grants, country co-financing ($302M in 2025), and capital-market borrowings to fund vaccine procurement at scale.
Gavi's product portfolio spans 20 infectious diseases and includes the Gavi 6.0 Strategic Framework (2026-2030), the Gavi Leap reform programme, the African Vaccine Manufacturing Accelerator (AVMA+, $189M), the First Response Fund for outbreak emergencies, and the VaccinesWork digital media platform. Its business model is a five-year replenishment cycle funded primarily by sovereign governments (over $9 billion secured for 2026-2030 from 55 countries and donors at the June 2025 Brussels summit, including $1.6B from the Gates Foundation), supplemented by country co-financing, innovative finance proceeds, and private sector partnerships. Distribution is handled through UNICEF as the primary procurement agent and through national immunization programmes in implementing countries. Since inception, Gavi has helped immunize over 1.2 billion children, avert 20.6 million future deaths, and generate $280+ billion in economic benefits across supported countries.
Gavi, the Vaccine Alliance firmographics
Firmographics- Name
- Gavi, the Vaccine Alliance
- Legal name
- The Gavi Alliance
- Website
- https://gavi.org
- Company type
- Private
- Founded year
- 2000
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Gavi, the Vaccine Alliance is a Geneva-based public-private partnership founded in 2000 that finances and coordinates immunization programmes across 78 lower-income countries, leveraging innovative finance, UNICEF procurement, and donor capital to vaccinate over half the world's children against 20 infectious diseases.
- Ownership category
- akta.pro rank
Gavi, the Vaccine Alliance industry classification
Industry- Product category
- Global Immunization Financing
- NAICS
- Voluntary Health Organizations (813212), Grantmaking and Giving Services (81321)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Immunization & Vaccine Access Partnerships (Global Vaccine Alliances) (HLAJAOAF)
- akta.pro secondary industries
- Immunization & Vaccine Delivery Programs (BPADAIAB), Infectious Disease & Immunization Program Funding (HLAJALAH), Funding, Reimbursement & Vaccines-for-Children (VFC)/Public Purchase Programs (HLAJAHAK)
Keywords
Where Gavi, the Vaccine Alliance is headquartered
LocationHeadquarters
- HQ city
- Geneva
- HQ country
- Switzerland
- HQ region
- Europe
Offices2 records
Markets served
Gavi, the Vaccine Alliance business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Operations, Personnel, Supply Chain, Marketing or Sales, Others
Revenue model
- Government Donor Funding: Gavi is funded by sovereign governments through five-year replenishment cycles. Donor governments contribute based on GDP and other factors. At the June 2025 Brussels summit, over $9 billion was secured from 55 countries and donors for the 2026-2030 strategic period.
- Foundation and Private Sector Contributions: Major foundations including the Gates Foundation provide substantial grants. The Gates Foundation contributed $1.6 billion at the 2025 replenishment. Corporate partners contribute through the Gavi Matching Fund and other innovative financing mechanisms.
- Country Co-Financing: Implementing countries contribute to the cost of vaccines through co-financing arrangements. Lower-income countries collectively invested a record US$302 million in 2025, with countries contributing $1.1 billion over the past five years.
- Innovative Finance Mechanisms: Gavi leverages IFFIm to raise finance in international capital markets to support programmes. The Pneumococcal Advance Market Commitment (AMC) incentivizes vaccine development through guaranteed purchase commitments.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Multi-year contract | R21 malaria vaccine pricing agreement with UNICEF |
| Unit Pricing | Annual | Pneumococcal conjugate vaccine for lower-income countries |
Go-to-market motion2 records
Distribution channels5 records
Marketing channels7 records
Gavi, the Vaccine Alliance product offering
Product offeringCore offering
Gavi funds and coordinates the procurement, introduction, and delivery of vaccines against 20 infectious diseases (including Ebola, malaria, mpox, HPV, and routine childhood immunizations) for 78 lower-income countries. It does not sell products directly; instead it pools donor commitments, negotiates affordable pricing with manufacturers, channels vaccines through UNICEF, and provides co-financing and technical assistance to country governments running national immunization programmes.
Product overview
Gavi, the Vaccine Alliance is a public-private partnership that helps vaccinate more than half the world's children against some of the world's deadliest diseases. Rather than a unified software product, Gavi operates as a coordination and funding mechanism offering multiple programs including the Gavi 6.0 Strategic Framework (2026-2030), the Gavi Leap reform program, the African Vaccine Manufacturing Accelerator (AVMA+), the First Response Fund for outbreak emergencies, the COVAX Rapid Financing Facility, the Digital Health Information Strategy, and the VaccinesWork digital media platform. Gavi supports vaccines against 20 infectious diseases including Ebola, malaria, mpox, HPV, and rabies, spanning vaccine support, health systems strengthening, and market shaping activities.
Differentiator
Problem solved
Functional benefit
Brands
- VaccinesWork: Award-winning digital platform hosted by Gavi covering news, features and explainers from every corner of global health and immunisation.
- Gavi Leap
- COVAX
- AVMA+ (African Vaccine Manufacturing Accelerator)
Products and services
- Gavi 6.0 Strategic Framework (2026–2030) Five-year strategic framework providing access to Gavi's portfolio of life-saving vaccines for implementing country governments and partners during the 2026–2030 period.
- African Vaccine Manufacturing Accelerator (AVMA+) Accelerator programme providing guaranteed procurement, technology transfer support, and capacity building to African vaccine manufacturers, addressing regulatory and market-entry bottlenecks.
- First Response Fund Surge-financing mechanism enabling rapid deployment of vaccines during outbreaks and epidemics, with agile coalition financing for Day Zero intervention.
- COVAX Rapid Financing Facility Financing facility providing up to US$1 billion to accelerate purchase and delivery of COVID-19 vaccines and supplies for developing countries, in partnership with the US DFC.
- R21/Matrix-M Malaria Vaccine Programme Affordable malaria vaccine procurement programme offering R21/Matrix-M at $2.99 per dose to supported countries, with multi-year pricing agreement covering 25 African countries.
- VaccinesWork Digital Platform
Quantifiable outcome
- 1.2 billion children vaccinated, 20.6 million deaths averted, $280+ billion in economic benefits since 2000
- +4 more outcomes
Companies that use Gavi, the Vaccine Alliance
Customer profileNamed customers8 records
Segments4 records
Ideal customer profiles3 records
Gavi, the Vaccine Alliance technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Gavi, the Vaccine Alliance partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered flagship and core.
- UNICEF (Bundibugyo Ebola Initiative)flagshipUNICEF and Gavi jointly launched a Request for Expression of Interest for Bundibugyo Ebola vaccine development. UNICEF issued the EOI inviting developers to submit vaccine candidate details, with Gavi committing $50 million through its First Response Fund to support manufacturing and rapid deployment.
- PfizercorePfizer supplies pneumococcal conjugate vaccines on a not-for-profit basis to 57 Gavi-eligible countries. Pfizer reached the milestone of 1 billion doses supplied through Gavi, with the milestone dose delivered to Ethiopia's national immunization programme. The collaboration has protected over 300 million children from pneumococcal disease.
- UNICEFcoreUNICEF is the world's largest buyer and supplier of vaccines for developing countries and serves as a pivotal partner in the Vaccine Alliance. UNICEF handles procurement and supply chain logistics for Gavi-supported vaccines, reaching children in the most remote and underserved communities through national immunization programmes.
- World Health Organization (WHO)coreAs the UN's specialist agency on global health issues, WHO provides technical expertise and normative guidance to the Vaccine Alliance. WHO sets immunization policies, provides country-level technical assistance, and coordinates outbreak response through global health emergency mechanisms.
- World BankcoreThe World Bank brings expertise in development financing to the Vaccine Alliance, providing loans, grants, and technical assistance for health system strengthening in implementing countries. The Bank supports countries to finance immunization programmes and transition to sustainable domestic financing.
- CEPI (Coalition for Epidemic Preparedness Innovations)coreCEPI coordinates with Gavi on outbreak vaccine development, including the urgent plan for Bundibugyo Ebola vaccine response. CEPI and Gavi issued joint calls for accelerating vaccine access during the 2026 Ebola outbreak caused by the Bundibugyo virus.
Scale indicators23 records
Recent moves8 records
Expansion highlights6 records
Gavi, the Vaccine Alliance competitors and assessment
Company assessmentDirect peers
- UNICEF Supply Division: UNICEF is Gavi's primary procurement partner and the world's largest vaccine buyer for developing countries, executing bulk procurement and supply chain logistics on Gavi's behalf. The two organizations are operationally intertwined, with UNICEF handling the physical vaccine distribution while Gavi provides financing.
- Gavi (Global Alliance for Vaccines and Immunization): Listed as the anchor; included for completeness as the primary reference entity.
- The Global Fund to Fight AIDS, Tuberculosis and Malaria: Parallel global health financing partnership using similar multi-donor replenishment model to fund disease control programs in lower-income countries. Directly comparable in structure, governance (public-private board), and 5-year replenishment cycle approach to mobilizing billions for health programs.
- Coalition for Epidemic Preparedness Innovations (CEPI): Direct partner and peer in the global vaccine ecosystem, co-leading COVAX with Gavi. CEPI focuses on vaccine R&D for epidemic threats while Gavi handles procurement and delivery — making them complementary but comparable in mission and donor base.
- PATH: Global health non-profit with deep vaccine programs including the Malaria Vaccine Initiative and significant involvement in introducing new vaccines in lower-income countries. Comparable to Gavi as a coordinating and financing entity for vaccine access programs.
- Clinton Health Access Initiative (CHAI): Works in lower-income countries on market-shaping for vaccines, medicines, and diagnostics, with overlapping country relationships to Gavi's. CHAI negotiates pricing and supports health system strengthening in similar geographies, making it a comparable operator in vaccine access.
Broad incumbents
- World Health Organization (WHO): Gavi's core institutional partner and a broader incumbent in global health governance. WHO sets immunization policy and provides technical guidance that Gavi finances, creating overlapping mandate in global health architecture.
- Bill & Melinda Gates Foundation: Gavi's largest single donor ($1.6B at 2025 replenishment, $750M founding seed) and a broader incumbent in global health financing. The Foundation operates across a far wider portfolio but is the closest comparable funder of immunization and global health systems.
- Wellcome Trust: Major UK-based foundation funding global health research and epidemic preparedness. Contributes to CEPI and various vaccine initiatives, making it a comparable funder with overlapping donor relationships to Gavi.
Emerging players
- Medicines for Malaria Venture (MMV): Product development partnership focused on malaria treatments and now adjacent in malaria vaccines, with a similar donor-funded, multi-stakeholder structure. Operates at smaller scale than Gavi but is comparable in public-private partnership model and malaria focus.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat6 records
Key risks5 records
Key highlights7 records
Customer concentration
Gavi, the Vaccine Alliance social profiles
Digital presenceGavi, the Vaccine Alliance compliance and trust
Trust signalCompliance1 record
Gavi, the Vaccine Alliance financial estimates
Financial estimateRevenue estimate
Valuation estimate
Gavi, the Vaccine Alliance leadership team
Management profileNumber of profiles
Profiles14 records
Gavi, the Vaccine Alliance subsidiaries and ownership
Company hierarchySubsidiaries1 record
Gavi, the Vaccine Alliance funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Gavi, the Vaccine Alliance M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Gavi, the Vaccine Alliance
What does Gavi, the Vaccine Alliance do?
Gavi funds and coordinates the procurement, introduction, and delivery of vaccines against 20 infectious diseases (including Ebola, malaria, mpox, HPV, and routine childhood immunizations) for 78 lower-income countries. It does not sell products directly; instead it pools donor commitments, negotiates affordable pricing with manufacturers, channels vaccines through UNICEF, and provides co-financing and technical assistance to country governments running national immunization programmes.
Is Gavi, the Vaccine Alliance a public or private company?
Gavi, the Vaccine Alliance is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was Gavi, the Vaccine Alliance founded?
Gavi, the Vaccine Alliance was founded in 2000. It employs 51 to 100 people.
Where is Gavi, the Vaccine Alliance based?
Gavi, the Vaccine Alliance is headquartered in Geneva, Switzerland, in the Europe region.
How does Gavi, the Vaccine Alliance make money?
Four revenue lines are on record. Government Donor Funding is the primary driver. The others are foundation and Private Sector Contributions, country Co-Financing and innovative Finance Mechanisms.
Who are Gavi, the Vaccine Alliance's main competitors?
Direct peers on record are UNICEF Supply Division, Gavi (Global Alliance for Vaccines and Immunization), The Global Fund to Fight AIDS, Tuberculosis and Malaria, Coalition for Epidemic Preparedness Innovations (CEPI), PATH and Clinton Health Access Initiative (CHAI). Broad incumbents are World Health Organization (WHO), Bill & Melinda Gates Foundation and Wellcome Trust. Medicines for Malaria Venture (MMV) is listed as an emerging player.
Does Gavi, the Vaccine Alliance have an API?
No public API is recorded for Gavi, the Vaccine Alliance.
What industry is Gavi, the Vaccine Alliance in?
Gavi, the Vaccine Alliance's product category is Global Immunization Financing. Its primary akta.pro industry code is HLAJAOAF, Immunization & Vaccine Access Partnerships (Global Vaccine Alliances), with a secondary code of BPADAIAB, Immunization & Vaccine Delivery Programs. Its NAICS code is 813212 and its SIC code is 2836.